3
Announcements
Trials
Browse
Landscape
Status
Terminated
8
Completed
7
Active not recruiting
4
Unknown
3
Recruiting
2
No longer available
1
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
ponatinib
1
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Approved for marketing
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
ponatinib
×
Clear all
NCT01592136
2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing